Highest-materiality recent filing
Avanos Medical to be acquired by AIP for $25/share, $1.272B enterprise value
Avanos stockholders receive $25.00 per share in cash; enterprise value approx. $1.272B.
Avanos adds two directors in cooperation deal with activist Radoff
James Cunniff (CEO of Electromed) and William Burke (former EVP/CFO Haemonetics) nominated for board at 2026 annual meeting.
Avanos reports Q4 adjusted EPS $0.29 vs $0.43 prior year; FY2025 sales $701.2M up 1.9%
Q4 net sales $180.9M (+0.7% YoY); SNS segment up 8.7% to $115.1M; PM&R up 1.3% to $61.6M.
Avanos Medical acquires Nexus Medical for TKO anti-reflux connector; accretive to revenue/ EPS
Acquisition of Nexus Medical, LLC, maker of TKO needleless connector technology for NICU/PICU.
Avanos Q2 net loss $76.8M, goodwill impairment $77M; HA divestiture completed July 31
Q2 net sales $175M (+1.9% YoY); net loss $76.8M vs $4.3M income a year ago.
Avanos Q1 EPS $0.14, adjusted EPS $0.26; cuts 2025 adj. EPS view to $0.75-$0.95 on tariffs
Net sales $167.5M (+0.8% YoY); organic net sales up 2.8%.
Avanos appoints Jason Pickett as Interim CFO; Greiner departs with $2.1M severance
Michael Greiner departs after not being offered comparable role post-interim CEO; receives $2.1M severance, prorated bonus, $50K consulting fee.
Avanos CFO transition: Greiner departs, Pickett named Interim CFO
Michael Greiner leaves Avanos effective April 18, 2025; receives $2.1M severance, prorated 2025 bonus, and 6 months COBRA.
Avanos Medical names David Pacitti as CEO, effective April 14, 2025
David Pacitti appointed CEO of Avanos Medical, effective April 14, 2025.
CEO Joseph Woody retires; CFO Michael Greiner named interim CEO; Warren Machan interim CFO
Joseph Woody retired as CEO and board member effective Oct 28, 2024; will consult through Apr 30, 2025 at $84,618/month.
Q4 net sales $173.3M (-4.6% YoY); full-year net sales $673.3M (-1.6%) on lower HA sales.
On April 28, 2025, Avanos Medical, Inc. (the “Company”) and Michael C. Greiner entered into a Separation and Consulting Agreement (the “Separation and Consulting Agreement”).
Mr. Machan no longer serves as the Company’s Interim Chief Financial Officer effective April 14, 2025
On April 18, 2025, Michael C. Greiner announced that he will leave the Company to pursue other opportunities because the Company did not offer him a position comparable to the one he held prior to his role as the Company’s Interim Chief Executive Officer.
The Company has appointed Jason M. Pickett as Interim Chief Financial Officer and Treasurer, effective April 14, 2025.
On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.
Mr. Machan no longer serves as the Company’s Interim Chief Financial Officer effective April 14, 2025
The Company has appointed Jason M. Pickett as Interim Chief Financial Officer and Treasurer, effective April 14, 2025.
On April 18, 2025, Michael C. Greiner announced that he will leave Avanos Medical, Inc. (the “Company”) to pursue other opportunities because the Company did not offer him a position comparable to the one he held prior to his role as the Company’s Interim Chief Executive Officer.
On March 17, 2025, Avanos Medical, Inc. (the “Company”) announced the appointment of David Pacitti as the Company’s Chief Executive Officer, effective April 14, 2025.
the Company appointed Michael C. Greiner to serve as Interim Chief Executive Officer of the Company.
On October 28, 2024, the Company announced the retirement of Joseph F. Woody as Chief Executive Officer and a member of the Board of Directors of the Company, effective immediately.
On June 28, 2024, the Board of Directors (the “Board”) of Avanos Medical, Inc. (the “Company”) appointed Indrani Franchini to the Board, effective July 1, 2024.
Max materiality 1.00 · Median 0.50 · Most common event leadership